Management strategies for autoimmune pancreatitis

Abstract

Introduction: Autoimmune pancreatitis (AIP) is a newly developed concept for a peculiar type of pancreatitis, and at present is recognized as a pancreatic lesion reflecting IgG4-related systemic disease. It is of utmost importance to differentiate AIP from pancreatic cancer to avoid unnecessary surgery.

Areas covered: The current management strategies for AIP, including its clinical features, diagnostic criteria, clinical subtypes, steroid therapy and prognosis are discussed, based on our 66 AIP cases and papers searched in PubMed from 1992 to March 2011, using the term ‘autoimmune pancreatitis’. A new clinicopathological entity, an ‘IgG4-related sclerosing disease’ is also mentioned.

Expert opinion: AIP should be considered in the differential diagnosis in elderly male patients presented with obstructive jaundice and pancreatic mass. Steroids are a standard therapy for AIP, but their regimen including maintenance therapy should be evaluated in prospective trials.

Keywords::

• autoimmune pancreatitis
• IgG4
• IgG4-related sclerosing cholangitis
• steroid

Acknowledgement

This study was supported by Research for Intractable Disease of the Pancreas, Ministry of Labor and Welfare of Japan.

Notes

This box summarizes key points contained in the article.